当前位置: X-MOL 学术Expert Rev. Mol. Diagn. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA
Expert Review of Molecular Diagnostics ( IF 5.1 ) Pub Date : 2021-06-14 , DOI: 10.1080/14737159.2021.1935881
Vincenza Conteduca 1 , Nicole Brighi 1 , Donato Conteduca 2 , Sara Bleve 1 , Caterina Gianni 1 , Giuseppe Schepisi 1 , Maria Laura Iaia 1 , Giorgia Gurioli 1 , Cristian Lolli 1 , Ugo De Giorgi 1
Affiliation  

ABSTRACT

Introduction: Prostate cancer is one of the most frequent tumors worldwide. Due to the lack of reliable markers, patients are usually diagnosed at a late stage when it becomes castration-resistant prostate cancer (CRPC) with a worse outcome. Thus, it is essential to ameliorate the clinical management of these patients. Nowadays, the use of liquid biopsy represents a minimally invasive way to provide a complete molecular landscape of prostate cancer. Thus, this review aims to outline the clinical value of cell-free DNA in real-time monitoring of metastatic CRPC (mCRPC).

Areas covered: This comprehensive review explores in detail the characteristics as well as clinical applications of plasma DNA analysis in mCRPC.

Expert opinion: The assessment of circulating tumor DNA fraction is a valid and robust biomarker in mCRPC able to predict clinical outcome and monitor disease evolution during treatment. Recently, several methods (i.e. next generation sequencing and digital droplet PCR) are used to investigate genomics in cell-free DNA and novel nanotechnology-based approaches are currently under evaluation in order to improve clinical management of mCRPC patients.



中文翻译:

我们用无细胞 DNA 监测去势抵抗性前列腺癌动态的能力的更新

摘要

简介:前列腺癌是全球最常见的肿瘤之一。由于缺乏可靠的标志物,患者通常在晚期被诊断为去势抵抗性前列腺癌 (CRPC),结果更差。因此,必须改善这些患者的临床管理。如今,液体活检的使用代表了一种提供前列腺癌完整分子图谱的微创方法。因此,本综述旨在概述游离 DNA 在实时监测转移性 CRPC (mCRPC) 中的临床价值。

涵盖的领域:这篇全面的综述详细探讨了血浆 DNA 分析在 mCRPC 中的特征和临床应用。

专家意见:循环肿瘤 DNA 分数的评估是 mCRPC 中有效且可靠的生物标志物,能够预测临床结果并监测治疗期间的疾病进展。最近,几种方法(即下一代测序和数字液滴 PCR)被用于研究无细胞 DNA 中的基因组学,并且目前正在评估基于纳米技术的新方法,以改善 mCRPC 患者的临床管理。

更新日期:2021-07-13
down
wechat
bug